Spotlight
Clinical
Conferences
CME/CE
Exelixis/BMS to develop XL139, hedgehog pathway inhibitor
Oncology NEWS InternationalOncology NEWS International Vol 17 No 2
Volume 17
Issue 2
Exelixis, Inc. and Bristol-Myers Squibb Company will collaborate to co-develop and co-commercialize Exelixis' compound XL139, a small molecule inhibitor of the hedgehog pathway, in the United States.
SOUTH SAN FRANCISCO, CaliforniaExelixis, Inc. and Bristol-Myers Squibb Company will collaborate to co-develop and co-commercialize Exelixis' compound XL139, a small molecule inhibitor of the hedgehog pathway, in the United States. Hedgehog plays a critical role in regulating cell growth, proliferation, and differentiation, and is deregulated in a variety of cancers, making it a promising target for cancer therapies, Exelixis said.
Articles in this issue
NLST article not balanced, critic of screening trial asserts
M.D. Anderson and AstraZeneca form neuropathic pain alliance
Good nilotinib responses in imatinib-resistant AP-CML
Virus linked to Merkel cell carcinoma
Benefit of adjuvant RT/CT for pancreatic ca affirmed
Recurrence Score helps select node+ pts for chemo
For resectable liver mets: Preop chemotherapy or not?
Plerixafor boosts stem cell mobilization in myeloma pts
MRI shows second-hand smoke damage
Assay has high sensitivity for hard-to-detect SLN mets
Dasatinib effective in imatinib resistant/intolerant CML
ONI remembers Judah Folkman, founder of angiogenesis
New machine approved for adaptive RT
ONI sits down with Dr. Vincent DeVita
Making faster, better, more cost-effective clinical trials
Related Videos
Related Content
